Ligand Pharmaceuticals (FRA:LGDN) FFO


FRA:LGDN Ligand Pharmaceuticals Inc FRA:LGDN
76 GF Score
Price €254.00
GF Value €147.69
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Ligand Pharmaceuticals FFO?

FFO (Funds from operations) only applies to REITs.

FRA:LGDN
76GF Score
Ligand Pharmaceuticals Inc FRA:LGDN
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Ligand Pharmaceuticals (FRA:LGDN) Overvalued in 2026?

Based on GuruFocus' analysis, Ligand Pharmaceuticals stock appears to be overvalued. The current stock price of €254.00 is trading 72% above its estimated GF Value™ of €147.69. GuruFocus considers Ligand Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for FRA:LGDN:

  • FFO:
  • GF Value™: €147.69 vs. price of €254.00 (72% above fair value)
  • GF Score™: 76/100 with 5 warning signs

No single metric tells the full story. See the FRA:LGDN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ligand Pharmaceuticals Business Description

Other Exchanges LGND:USA
Address 555 Heritage Drive, Suite 200, Jupiter, FL, USA, 33458
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
76GF Score

Get the complete analysis for FRA:LGDN

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€254.00
Price
€147.69
GF Value